Since CUL4A has been previously reported to be overexpressed in nasopharyngeal and esophageal squamous cell carcinoma, this provides further rationale for the investigation of pevonedistat for HNSCC therapy [42, 43]. This evidence concerns the gene CUL4A and head and neck squamous cell carcinoma.